Data gathered: November 27
AI Stock Analysis - Cabaletta Bio (CABA)
Analysis generated June 5, 2024. Powered by Chat GPT.
Cabaletta Bio is a biotechnology company focusing on engineering cell therapies aimed at potential treatment for autoimmune diseases. The company leverages its Cabaletta Approach platform to produce and develop highly specialized therapies that target the root cause of disease at a cellular level. Despite its promising pipeline, Cabaletta Bio is currently in the developmental stage, and its financials reflect the costs associated with rigorous research and development processes.
Stock Alerts - Cabaletta Bio (CABA)
 |
Cabaletta Bio | November 27 Price is up by 5.8% in the last 24h. |
|
Cabaletta Bio | November 26 Price is up by 8.3% in the last 24h. |
|
Cabaletta Bio | November 25 Price is up by 5.9% in the last 24h. |
|
Cabaletta Bio | November 21 Price is down by -5.8% in the last 24h. |
Alternative Data for Cabaletta Bio
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 90 | Sign up | Sign up | Sign up |
| Google Trends | 10 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 23 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,966 | Sign up | Sign up | Sign up |
| Twitter Followers | 462 | Sign up | Sign up | Sign up |
| Twitter Mentions | 20 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 169 | Sign up | Sign up | Sign up |
About Cabaletta Bio
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
| Price | $3.01 |
| Target Price | Sign up |
| Volume | 4,100,000 |
| Market Cap | $112M |
| Year Range | $1.87 - $18.82 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Cabaletta Bio to Participate in Upcoming Investor Conferences in DecemberNovember 25 - Yahoo |
 |
Cabaletta Bio (NASDAQ:CABA) Discloses Promising Clinical Data from ACR Convergence 2024 ConferenceOn November 18, 2024, Cabaletta Bio, Inc. released pivotal information from the American College of Rheumatology (ACR) Convergence 2024 conference. TheNovember 20 - ETF Daily News |
|
Cabaletta Bio’s (CABA) “Outperform” Rating Reiterated at William BlairNovember 19 - ETF Daily News |
 |
Wells Fargo & Company Cuts Cabaletta Bio (NASDAQ:CABA) Price Target to $12.00November 18 - ETF Daily News |
|
Cabaletta Bio (NASDAQ:CABA) Receives Buy Rating from HC WainwrightNovember 17 - ETF Daily News |
|
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024November 17 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 6.8M | -6.8M | -31M | -33M | -0.620 |
| Q2 '24 | 0 | 6.9M | -6.9M | -28M | -30M | -0.560 |
| Q1 '24 | 0 | 6.3M | -6.3M | -25M | -28M | -0.510 |
| Q4 '23 | 4M | 5.9M | -5.9M | -21M | -23M | -0.460 |
| Q3 '23 | 0 | 4.9M | -4.9M | -16M | -19M | -0.370 |
Insider Transactions View All
| Binder Gwendolyn filed to sell 20,000 shares at $20.3. January 19 '24 |
| Binder Gwendolyn filed to sell 20,700 shares at $19.5. January 19 '24 |
| Binder Gwendolyn filed to sell 20,000 shares at $22.2. December 19 '23 |
| Binder Gwendolyn filed to sell 23,132 shares at $21.8. December 19 '23 |
| Binder Gwendolyn filed to sell 27,458 shares at $17.4. November 21 '23 |
Similar companies
Read more about Cabaletta Bio (CABA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Cabaletta Bio?
The Market Cap of Cabaletta Bio is $112M.
What is the current stock price of Cabaletta Bio?
Currently, the price of one share of Cabaletta Bio stock is $3.01.
How can I analyze the CABA stock price chart for investment decisions?
The CABA stock price chart above provides a comprehensive visual representation of Cabaletta Bio's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cabaletta Bio shares. Our platform offers an up-to-date CABA stock price chart, along with technical data analysis and alternative data insights.
Does CABA offer dividends to its shareholders?
As of our latest update, Cabaletta Bio (CABA) does not offer dividends to its shareholders. Investors interested in Cabaletta Bio should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Cabaletta Bio?
Some of the similar stocks of Cabaletta Bio are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.